<DOC>
	<DOCNO>NCT02926430</DOCNO>
	<brief_summary>The purpose study assess safety tolerability 2 single dos either 5*10^10 viral particle ( vp ) 1*10^11 vp Ad26.RSV.preF , administer intramuscularly elderly adult give least 12 month apart .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Immunogenicity Two Vaccinations Ad26.RSV.preF One Year Apart Adults Aged 60 Years Older Stable Health</brief_title>
	<detailed_description />
	<criteria>Each participant must sign informed consent form ( ICF ) indicate understands purpose procedure require study , willing participate study attend schedule visit , willing able comply study procedure adhere prohibition restriction specify protocol Before randomization , woman must : postmenopausal A postmenopausal state define menses 12 month without alternative medical cause ; intend conceive method From time first vaccination 3 month first dose study vaccine , second vaccination 3 month , man vasectomy ( vasectomy perform less 1 year ago absence sperm verify ) In investigator 's clinical judgment , participant must either good stable health . Participants may underlie illness hypertension , type 2 diabetes , hyperlipoproteinemia , hypothyroidism , long symptoms/signs medically control . If medication condition , medication dose must stable least 12 week precede vaccination expect remain stable duration study . Participants include basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform screen Participant must healthy basis clinical laboratory test perform screen . If result laboratory screening test outside central laboratory normal reference range additionally within limit toxicity Grades 1 2 accord US Food Drug Administration ( FDA ) toxicity table ( test FDA table ) , participant may include investigator judge abnormalities deviation normal clinically significant appropriate reasonable population study . This determination must record participant 's source document initial investigator Participant acute illness ( include minor illness diarrhea ) temperature great equal ( &gt; = ) 38.0 degree celsius within 24 hour prior first dose study vaccine ; enrollment later date permit Participant serious chronic disorder , include severe chronic obstructive pulmonary disease clinically significant congestive heart failure , requirement supplemental oxygen , end stage renal disease without dialysis , clinically unstable cardiac disease , Alzheimer 's disease , condition , opinion investigator , participation would best interest participant ( example , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment Participant major surgery within 4 week prior randomization plan major surgery course study Participant chronic active hepatitis B hepatitis C infection , document hepatitis B surface antigen hepatitis C antibody , respectively Participant human immunodeficiency virus ( HIV ) type 1 type 2 infection</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>